These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 15148149)

  • 21. White Matter Hyperintensities in Mild Cognitive Impairment and Lower Risk of Cognitive Decline.
    Nolze-Charron G; Mouiha A; Duchesne S; Bocti C;
    J Alzheimers Dis; 2015; 46(4):855-62. PubMed ID: 26402625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.
    Gomar JJ; Bobes-Bascaran MT; Conejero-Goldberg C; Davies P; Goldberg TE;
    Arch Gen Psychiatry; 2011 Sep; 68(9):961-9. PubMed ID: 21893661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebral white matter lesions in patients with dementia - from MCI to severe Alzheimer's disease.
    Targosz-Gajniak M; Siuda J; Ochudło S; Opala G
    J Neurol Sci; 2009 Aug; 283(1-2):79-82. PubMed ID: 19268974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
    Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design.
    van Rossum IA; Vos S; Handels R; Visser PJ
    J Alzheimers Dis; 2010; 20(3):881-91. PubMed ID: 20413876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.
    Brys M; Pirraglia E; Rich K; Rolstad S; Mosconi L; Switalski R; Glodzik-Sobanska L; De Santi S; Zinkowski R; Mehta P; Pratico D; Saint Louis LA; Wallin A; Blennow K; de Leon MJ
    Neurobiol Aging; 2009 May; 30(5):682-90. PubMed ID: 17889968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
    Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
    J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ApoE alleles and tau markers in patients with different levels of cognitive impairment.
    Lavados M; Farías G; Rothhammer F; Guillon M; Mujica MC; Maccioni C; Maccioni RB
    Arch Med Res; 2005; 36(5):474-9. PubMed ID: 16099324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing CSF phospho-tau levels during cognitive decline and progression to dementia.
    Andersson C; Blennow K; Almkvist O; Andreasen N; Engfeldt P; Johansson SE; Lindau M; Eriksdotter-Jönhagen M
    Neurobiol Aging; 2008 Oct; 29(10):1466-73. PubMed ID: 17512092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment.
    Jessen F; Wiese B; Bachmann C; Eifflaender-Gorfer S; Haller F; Kölsch H; Luck T; Mösch E; van den Bussche H; Wagner M; Wollny A; Zimmermann T; Pentzek M; Riedel-Heller SG; Romberg HP; Weyerer S; Kaduszkiewicz H; Maier W; Bickel H;
    Arch Gen Psychiatry; 2010 Apr; 67(4):414-22. PubMed ID: 20368517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study.
    Reijs BLR; Vos SJB; Soininen H; Lötjonen J; Koikkalainen J; Pikkarainen M; Hall A; Vanninen R; Liu Y; Herukka SK; Freund-Levi Y; Frisoni GB; Frölich L; Nobili F; Rikkert MO; Spiru L; Tsolaki M; Wallin ÅK; Scheltens P; Verhey F; Visser PJ
    J Alzheimers Dis; 2017; 60(4):1387-1395. PubMed ID: 29036813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.
    Arai H; Ishiguro K; Ohno H; Moriyama M; Itoh N; Okamura N; Matsui T; Morikawa Y; Horikawa E; Kohno H; Sasaki H; Imahori K
    Exp Neurol; 2000 Nov; 166(1):201-3. PubMed ID: 11031097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
    Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
    Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.
    Zetterberg H; Skillbäck T; Mattsson N; Trojanowski JQ; Portelius E; Shaw LM; Weiner MW; Blennow K;
    JAMA Neurol; 2016 Jan; 73(1):60-7. PubMed ID: 26524180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment.
    Simonsen AH; McGuire J; Hansson O; Zetterberg H; Podust VN; Davies HA; Waldemar G; Minthon L; Blennow K
    Arch Neurol; 2007 Mar; 64(3):366-70. PubMed ID: 17353378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
    Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG
    Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amnestic multiple cognitive domains impairment and periventricular white matter hyperintensities are independently predictive factors progression to dementia in mild cognitive impairment.
    Lee HK; Lee YM; Park JM; Lee BD; Moon ES; Chung YI
    Int J Geriatr Psychiatry; 2014 May; 29(5):526-32. PubMed ID: 24123391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment.
    Tabert MH; Manly JJ; Liu X; Pelton GH; Rosenblum S; Jacobs M; Zamora D; Goodkind M; Bell K; Stern Y; Devanand DP
    Arch Gen Psychiatry; 2006 Aug; 63(8):916-24. PubMed ID: 16894068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is there an MCI reversion to cognitively normal? Analysis of Alzheimer's disease biomarkers profiles.
    Park MH; Han C
    Int Psychogeriatr; 2015 Mar; 27(3):429-37. PubMed ID: 25255915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.